Cargando…

Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

Oligometastatic non-small cell lung cancer (NSCLC) describes an intermediate stage of NSCLC between localized and widely-disseminated disease. This stage of NSCLC is characterized by a limited number of metastases and a more indolent tumor biology. Currently, the management of oligometastatic NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Couñago, Felipe, Luna, Javier, Guerrero, Luis Leonardo, Vaquero, Blanca, Guillén-Sacoto, María Cecilia, González-Merino, Teresa, Taboada, Begoña, Díaz, Verónica, Rubio-Viqueira, Belén, Díaz-Gavela, Ana Aurora, Marcos, Francisco José, del Cerro, Elia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885452/
https://www.ncbi.nlm.nih.gov/pubmed/31799148
http://dx.doi.org/10.5306/wjco.v10.i10.318
_version_ 1783474741553659904
author Couñago, Felipe
Luna, Javier
Guerrero, Luis Leonardo
Vaquero, Blanca
Guillén-Sacoto, María Cecilia
González-Merino, Teresa
Taboada, Begoña
Díaz, Verónica
Rubio-Viqueira, Belén
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
del Cerro, Elia
author_facet Couñago, Felipe
Luna, Javier
Guerrero, Luis Leonardo
Vaquero, Blanca
Guillén-Sacoto, María Cecilia
González-Merino, Teresa
Taboada, Begoña
Díaz, Verónica
Rubio-Viqueira, Belén
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
del Cerro, Elia
author_sort Couñago, Felipe
collection PubMed
description Oligometastatic non-small cell lung cancer (NSCLC) describes an intermediate stage of NSCLC between localized and widely-disseminated disease. This stage of NSCLC is characterized by a limited number of metastases and a more indolent tumor biology. Currently, the management of oligometastatic NSCLC involves radical treatment (radiotherapy or surgery) that targets the metastatic lesions and the primary tumor to achieve disease control. This approach offers the potential to achieve prolonged survival in patients who, in the past, would have only received palliative measures. The optimal therapeutic strategies for the different scenarios of oligometastatic disease (intracranial vs extracranial disease, synchronous vs metachronous) remain undefined. Given the lack of head-to-head studies comparing radiotherapy to surgery in these patients, the decision to apply surgery or radiotherapy (with or without systemic treatment) must be based on prognostic factors that allow us to classify patients. This classification will allow us to select the most appropriate therapeutic strategy on an individualized basis. In the future, the molecular or microRNA profiles will likely improve the treatment selection process. The objective of the present article is to review the most relevant scientific evidence on the management of patients with oligometastatic NSCLC, focusing on the role of radiotherapy and surgery. We also discuss areas of controversy and future directions.
format Online
Article
Text
id pubmed-6885452
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-68854522019-12-03 Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions Couñago, Felipe Luna, Javier Guerrero, Luis Leonardo Vaquero, Blanca Guillén-Sacoto, María Cecilia González-Merino, Teresa Taboada, Begoña Díaz, Verónica Rubio-Viqueira, Belén Díaz-Gavela, Ana Aurora Marcos, Francisco José del Cerro, Elia World J Clin Oncol Review Oligometastatic non-small cell lung cancer (NSCLC) describes an intermediate stage of NSCLC between localized and widely-disseminated disease. This stage of NSCLC is characterized by a limited number of metastases and a more indolent tumor biology. Currently, the management of oligometastatic NSCLC involves radical treatment (radiotherapy or surgery) that targets the metastatic lesions and the primary tumor to achieve disease control. This approach offers the potential to achieve prolonged survival in patients who, in the past, would have only received palliative measures. The optimal therapeutic strategies for the different scenarios of oligometastatic disease (intracranial vs extracranial disease, synchronous vs metachronous) remain undefined. Given the lack of head-to-head studies comparing radiotherapy to surgery in these patients, the decision to apply surgery or radiotherapy (with or without systemic treatment) must be based on prognostic factors that allow us to classify patients. This classification will allow us to select the most appropriate therapeutic strategy on an individualized basis. In the future, the molecular or microRNA profiles will likely improve the treatment selection process. The objective of the present article is to review the most relevant scientific evidence on the management of patients with oligometastatic NSCLC, focusing on the role of radiotherapy and surgery. We also discuss areas of controversy and future directions. Baishideng Publishing Group Inc 2019-10-24 2019-10-24 /pmc/articles/PMC6885452/ /pubmed/31799148 http://dx.doi.org/10.5306/wjco.v10.i10.318 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Couñago, Felipe
Luna, Javier
Guerrero, Luis Leonardo
Vaquero, Blanca
Guillén-Sacoto, María Cecilia
González-Merino, Teresa
Taboada, Begoña
Díaz, Verónica
Rubio-Viqueira, Belén
Díaz-Gavela, Ana Aurora
Marcos, Francisco José
del Cerro, Elia
Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title_full Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title_fullStr Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title_full_unstemmed Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title_short Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
title_sort management of oligometastatic non-small cell lung cancer patients: current controversies and future directions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885452/
https://www.ncbi.nlm.nih.gov/pubmed/31799148
http://dx.doi.org/10.5306/wjco.v10.i10.318
work_keys_str_mv AT counagofelipe managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT lunajavier managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT guerreroluisleonardo managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT vaqueroblanca managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT guillensacotomariacecilia managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT gonzalezmerinoteresa managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT taboadabegona managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT diazveronica managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT rubioviqueirabelen managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT diazgavelaanaaurora managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT marcosfranciscojose managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections
AT delcerroelia managementofoligometastaticnonsmallcelllungcancerpatientscurrentcontroversiesandfuturedirections